Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/27/2010WO2010058030A1 New compounds
05/27/2010WO2010058020A1 Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
05/27/2010WO2010058019A1 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
05/27/2010WO2010058018A1 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
05/27/2010WO2010058017A1 Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
05/27/2010WO2010058006A1 Cdk inhibitor for the treatment of mesothelioma
05/27/2010WO2010057981A1 Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
05/27/2010WO2010057966A1 Use of cationic surfactants for the inactivation of toxins
05/27/2010WO2010057928A1 Aerosol formulation for the inhalation of beta agonists
05/27/2010WO2010057927A1 Aerosol formulation for the inhalation of beta agonists
05/27/2010WO2010057899A1 Cycloalkyl amino carbonyl derivatives as bradykinin-b1 receptor antagonists
05/27/2010WO2010057877A1 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
05/27/2010WO2010057870A1 Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
05/27/2010WO2010057869A1 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
05/27/2010WO2010057865A1 N- inden- 2 -yl- isopropylsulfonamides as ampa receptor potentiators
05/27/2010WO2010057856A1 Use of escin for treatment of type iv hypersensitivity reaction
05/27/2010WO2010057848A1 8-azabicyclo [3.2.1]oct-2-ene derivatives and their use as mono-amine neurotransmitter re-uptake inhibitors
05/27/2010WO2010057833A1 Compounds for treatment of duchenne muscular dystrophy
05/27/2010WO2010057811A2 Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry
05/27/2010WO2010057804A1 Fat emulsion for artificially feeding seriously ill intensive care patients
05/27/2010WO2010057795A1 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
05/27/2010WO2010057596A2 New therapy and medicament using integrin ligands for treating cancer
05/27/2010WO2010057594A1 Drug delivery system
05/27/2010WO2010057503A2 Long acting conserved natural functional groups curcumin
05/27/2010WO2010057449A2 A solid pharmaceutical composition with atorvastatin and telmisartan as the active substances
05/27/2010WO2010057443A1 Use of 9,10-anthraquinone compounds
05/27/2010WO2010057442A1 A optical isomer of benzene propanoic acid and its medicinal use
05/27/2010WO2010057430A1 Polymorph form l of erlotinib, methods of preparation and uses thereof
05/27/2010WO2010057418A1 A phenoxypyrimidine derivative, its preparation method and the use thereof
05/27/2010WO2010057317A1 Liposomal composition for convection-enhanced delivery to the central nervous centre
05/27/2010WO2010039529A3 Compositions and methods for the treament of inflammatory disease
05/27/2010WO2010038081A3 4-amino-5- (hetero) aryl-2-phenylamino-pyrimidine or pyridine and their use as dna gyrase and/or topoisomerase iv inhibitors
05/27/2010WO2010036638A3 Compounds for the treatment of inflammatory disorders
05/27/2010WO2010034006A3 The putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2.
05/27/2010WO2010031519A8 Transcutaneous compositions for specific immuno-modulatory treatment
05/27/2010WO2010028826A3 A method for the production of bioadhesive compact matrices
05/27/2010WO2010026213A3 Treatment of scleroderma
05/27/2010WO2010026110A3 6-substituted benzoxazines as 5-ht-5a receptor antagonists
05/27/2010WO2010020423A3 Methods for treating bleeding disorders
05/27/2010WO2010019914A3 Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
05/27/2010WO2010019911A3 1,4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions
05/27/2010WO2010019775A3 Methods of treating ras driven cancer in a subject
05/27/2010WO2010019718A3 Carrier nanoparticles and related compositions, methods and systems
05/27/2010WO2010019549A3 Indoprofen derivatives for promoting bone growth
05/27/2010WO2010018213A3 Spiroimidazole compounds suitable for the treatment of neurological disorders
05/27/2010WO2010017626A4 Compositions comprising terpene compounds for treating negative sensory phenomena
05/27/2010WO2010017403A3 Therapeutic compositions, devices and methods for observing treated tissues
05/27/2010WO2010017355A3 Small molecule inhibitors of retroviral assembly and maturation
05/27/2010WO2010017272A3 Method of treating neurological diseases
05/27/2010WO2010017055A3 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
05/27/2010WO2010013987A3 Extraction method for increasing liquiritigenin content in glycyrrhizae radix et rhizoma or glycyrrhizae radix extract
05/27/2010WO2010013978A3 Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity
05/27/2010WO2010013969A3 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt
05/27/2010WO2010013925A3 Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
05/27/2010WO2010013222A8 Pyrrole carboxylic acid derivatives as antibacterial agents
05/27/2010WO2010011926A3 A novel betaine cocrystal of epalrestat
05/27/2010WO2010009809A3 Active substance combinations consisting of an anis fruit extract and hyaluronic acid
05/27/2010WO2010005480A9 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
05/27/2010WO2010003078A3 Melt granulation process
05/27/2010WO2010002465A3 Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
05/27/2010WO2010000372A3 New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
05/27/2010WO2009156462A3 Organic compounds
05/27/2010WO2009155504A3 Methods for the modulation of angiogenesis
05/27/2010WO2009153178A3 Aryl ketone as mri
05/27/2010WO2009144704A3 siRNA COMPOUNDS FOR INHIBITING NRF2
05/27/2010WO2009140624A3 Glucokinase activators
05/27/2010WO2009068955A3 Polymorphs of a c-met/hgfr inhibitor
05/27/2010WO2009035927A8 Bis-cyclyl substituted ureas or amides as soluble epoxide hydrolase inhibitors
05/27/2010WO2009018367A3 Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine
05/27/2010WO2009001192A3 Novel compounds and their use
05/27/2010WO2006133835A8 Oral solid pharmaceutical formulation of the tubulin inhibitor indibulin
05/27/2010WO2006103261A9 Inhibitors of neurotrypsin and determination thereof
05/27/2010US20100132073 Sesquiterpenoid modifying enzymes
05/27/2010US20100132060 Therapeuting compositions comprising an rnai agent and a neurotrophic factor and methods of use thereof
05/27/2010US20100132058 Methods and materials for determining pain sensitivity and predicting and treating related disorders
05/27/2010US20100131258 Method for identifying protein synthesis inhibitors by ribosome structure
05/27/2010US20100130909 Treatment of barrett's esophagus using photodynamic therapy
05/27/2010US20100130908 Method of use of porphyrins in preparing a medicament for sonodynamic therapy and a method of sonodynamic therapy using porphyrins
05/27/2010US20100130623 Production of stilbenes in plant hairy root cultures and other root cultures
05/27/2010US20100130622 Pharmaceutical preparation for preventing and/or treating periodontal disease, agent for oral hygiene comprising thereof, and food comprising thereof
05/27/2010US20100130621 Use of hydroxytyrosol as anti-aging agent
05/27/2010US20100130620 Novel use of hydroxytyrosol and olive extracts/concentrates containing it
05/27/2010US20100130619 Pharmaceutical composition for parenteral administration of idebenone
05/27/2010US20100130618 Treatment of human disease conditions and disorders using vitamin k analogues and derivatives
05/27/2010US20100130617 Ethanolamine modulators of nmda receptor and muscarinic acetylcholine receptor
05/27/2010US20100130616 Salt of aliskiren with orotic acid
05/27/2010US20100130615 Sulfonylurea inhibitors of atp-sensitive potassium channels
05/27/2010US20100130614 ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF IL-1ra
05/27/2010US20100130613 ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF CD1d OR IL-10
05/27/2010US20100130612 Composition containing chitosan for sustained drug release
05/27/2010US20100130611 Omega 3 fatty acid formulations
05/27/2010US20100130610 Deodorization and stabilization of marine oils
05/27/2010US20100130609 Ester of Hexyldecanol Having Short-Chained Fatty Acids
05/27/2010US20100130608 Compositions and methods for reducing triglyceride levels
05/27/2010US20100130607 Neuroprotection in demyelinating diseases
05/27/2010US20100130606 Pharmaceutical compositions comprising fesoterodine
05/27/2010US20100130604 Use of rosmarinic acid in manufacture of medicaments for treating or preventing hepatic and renal diseases
05/27/2010US20100130603 Medicament for prophylactic and therapeutic treatment of dermatosis resulting from excessively advanced keratinization
05/27/2010US20100130600 Lipoprotein lipase and its effect on statin treatments
05/27/2010US20100130599 CYP2C9*8 Alleles Correlate With Decreased Warfarin Metabolism And Increased Warfarin Sensitivity
1 ... 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 ... 7860